Advertisement

Irish Journal of Medical Science (1971 -)

, Volume 185, Issue 2, pp 433–441 | Cite as

Demographic and clinical factors predicting retention in methadone maintenance: results from an Irish cohort

  • C. D. DarkerEmail author
  • J. Ho
  • G. Kelly
  • L. Whiston
  • J. Barry
Original Article

Abstract

Background

Retention in Methadone Maintenance Treatment (MMT) is superior to that of other therapies for opioid addiction, but with international retention rates around 50 % after 1 year of treatment, there remains a need for improved retention rates.

Aims

This study aimed to explore the demographic and clinical factors predicting retention in MMT.

Methods

Face-to-face surveys with MMT patients in a Dublin methadone clinic were conducted. Retention was assessed by the presence and duration of breaks in treatment at any stage.

Results

189 patients participated in the study. 46 % (n = 87) reported having at least one break in treatment, and the median duration of a break was 3 months. Age, current methadone dose and prescription of antipsychotic medication were significant predictors of retention. Patients who were older, single, living in their own home, on a higher dose of methadone, or taking antipsychotic medications had fewer breaks in treatment. Males tended to have significantly longer breaks. Patients reported that the main reasons for breaks were relapse into drug use (21.8 %, n = 19), incarceration (11.4 %, n = 10), weary of MMT (13.7 %, n = 12) or problems at the clinic (10.3 %, n = 9). Factors enabling regular attendance included wanting to get or stay clean (37.5 %, n = 51), avoidance of withdrawal symptoms (16.1 %, n = 22), methadone dependence (13.9 %, n = 19) and services provided (10.2 %, n = 14).

Conclusion

Patients who were older, single, living in their own home, on a higher dose of methadone, or taking antipsychotic medications had fewer breaks in treatment.

Keywords

Methadone maintenance therapy Retention Demographic factors Clinical factors 

Notes

Acknowledgments

We thank the patients involved in this research.

Conflict of interest

None to declare.

Ethical standard

The current study has been approved by the Drug Treatment Centre Board Ethics Committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of the Helsinki and its later amendments.

References

  1. 1.
    Addiction. EUEMCfDaD (2011) Annual report 2011: the state of the drug problems in Europe. EMCDDA, LuxembourgGoogle Scholar
  2. 2.
    Cox G, Comiskey C, Kelly P (2007) ROSIE findings 4: summary of 1-year outcomes: methadone modality. National Advisory Committee on Drugs, DublinGoogle Scholar
  3. 3.
    Board DTC (2012) Annual report 2011. Drug Treatment Centre Board, DublinGoogle Scholar
  4. 4.
    Farrell M, Barry J (2009) The introduction of the national opioid treatment protocol. HSE, DublinGoogle Scholar
  5. 5.
    Bellerose D, Carew AM, Lyons S (2011) Trends in treated problem drug use in Ireland 2005–2010. Health Research Board, DublinGoogle Scholar
  6. 6.
    Gonzalez G, Oliverto A, Kosten TR (2002) Treatment of heroin (diamorphine) addiction: current approaches and future prospects. Drugs 62(9):12CrossRefGoogle Scholar
  7. 7.
    Ward J, Bell J, Mattick R et al. (1996) Methadone maintenance therapy for opioid dependence: a guide to appropriate use. CNS Drugs 6(6):9CrossRefGoogle Scholar
  8. 8.
    Chekuria V, Gerberb D, Brodiec A, Krishnadasd R (2012) Premature ejaculation and other sexual dysfunctions in opiate dependent men receiving methadone substitution treatment. Addict Behav 37(1):2Google Scholar
  9. 9.
    Fredheim OMMK, Borchgrevink PC, Kaasa S, Dale O (2008) Clinical pharmacology of methadone for pain. Acta Anaesthesiol Scand 52:10CrossRefGoogle Scholar
  10. 10.
    Schmittner J, Schroeder J, Epstein D, Preston K (2005) Menstrual cycle length during methadone maintenance. Addiction 100:7CrossRefGoogle Scholar
  11. 11.
    Addiction. NCPoEMToO (1998) Effective medical treatment of opiate addiction. JAMA 280(22):7Google Scholar
  12. 12.
    Zhang L, Chow EPF, Zhuang X, Liang Y, Wang Y, Tang C, Ling L, Tucker JD, Wilson DP (2013) Methadone maintenance treatment participant retention and behavioural effectiveness in China: a systematic review and meta-analysis. PloS one 8(7):e68906 (1932–6203 (Electronic)) CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Kelly SM, O’Grady KE, Mitchell SG, Brown BS, Schwartz RP (2011) Predictors of methadone treatment retention from a multi-site study: a survival analysis. Drug Alcohol Depend 117(2–3):170–175CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Simpson DD, Joe GW, Brown BS (1997) Treatment retention and follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychol Addict Behav 11(4):294–307CrossRefGoogle Scholar
  15. 15.
    Gossop M, Marsden J, Stewart D (2001) NTORS after five years the national treatment outcome research study: changes in substance use, health and criminal behaviour during the five years after intake. Crown Copyright, LondonGoogle Scholar
  16. 16.
    Oliver P, Keen J, Rowse G, Ewins E, Griffiths L, Mathers N (2010) The effect of time spent in treatment and dropout status on rates of convictions, cautions and imprisonment over 5 years in a primary care-led methadone maintenance service. Addiction 105(4):732–739CrossRefPubMedGoogle Scholar
  17. 17.
    Cox J, Allard R, Maurais E, Haley N, Small C (2013) Predictors of methadone program non-retention for opioid analgesic dependent patients. J Subst Abuse Treat 44(1):52–60CrossRefPubMedGoogle Scholar
  18. 18.
    Cosusins G, Teljeur C, Motterlini N, McCowan C, Dimitrov BD, Fahey T (2011) Risk of drug-related mortality during periods of transition in methadone maintenance treatment: a cohort study. J Subst Abus Treat 41(3):8Google Scholar
  19. 19.
    Nosyk B, Marsh D, Sun H, Schechter M, Anis A (2010) Trends in methadone maintenance treatment participation, retention, and compliance to dosing guidelines in British Columbia, Canada: 1996–2006. J Subst Abuse Treat 39(1):9CrossRefGoogle Scholar
  20. 20.
    National Institute of Drug Abuse (2007) National institute on drug abuse international programme. National Institute on Drug Abuse, BethesdaGoogle Scholar
  21. 21.
    Huissoud T, Rousson V, Dubuois-Arber F (2012) Methadone treatments in a Swiss Region, 2001–2008: a registry-based analysis. BMC Psychiatry 12:238CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Mullen L, Barry L, Long J, Keenan E, Mulholland D, Grogan L, Delargy I (2012) A national study of the retention of Irish opiate users in methadone subsitution treatment. Am J Drug Alcohol Abus 38:6CrossRefGoogle Scholar
  23. 23.
    Burns L, Randall D, Hall WD, Law M, Butler T, Bell J, Degenhardt L (2009) Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention. Addiction 104(8):1363–13672CrossRefPubMedGoogle Scholar
  24. 24.
    Zhou K, Zhuang G, Zhuang G. Retention in methadone maintenance treatment in mainland China, 2004–2012: a literature review. doi: 10.1016/j.addbeh.2013.09.001 (1873-6327(Electronic))
  25. 25.
    Ren J, Ning Z, Asche CV, Zhuang M, Kirkness CS, Ye X, Fu J, Pan Q (2013) Trends and predictors in methadone maintenance treatment dropout in Shanghai, China: 2005–2011. Curr Med Res Opin 29(7):731–738CrossRefPubMedGoogle Scholar
  26. 26.
    Peles E, Schreiber S, Adelson M (2010) 15-Year survival and retention of patients in a general hospital-affiliated methadone maintenance treatment (MMT) center in Israel. Drug Alcohol Depend 107(2–3):7Google Scholar
  27. 27.
    Villafranca SW, McKellar JD, Trafton JA, Humpfreys K (2006) Predictors of retention in methadone programs: a signal detection analysis. Drug Alcohol Depend 83:6CrossRefGoogle Scholar
  28. 28.
    Brady TM, Salvucci S, Sverdlov LS, Male A, Kyeyune H, Sikali E, DeSale S, Yu P (2005) Methadone dosage and retention: an examination of the 60 mg/day threshold. J Addict Dis 24(3):23–47CrossRefPubMedGoogle Scholar
  29. 29.
    Faggiano F, Vigna-Taglianti F, Versino E, Lemma P (2003) Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 3:1–47Google Scholar
  30. 30.
    Reisinger HS, Schwartz RP, Mitchell SG, Peterson JA, Kelly SM, O’Grady KE et al (2009) Premature discharge from methadone treatment: patient perspectives. J Psychoactive Drugs 41(3):285–296CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Deck D, Carlson M (2005) Retention in publicly funded methadone maintenance treatment in two Western States. J Behav Health Serv Res 32(1):17CrossRefGoogle Scholar
  32. 32.
    Hser Y, Anglin M, Liu Y (1990–1991) A survival analysis of gender and ethnic differences in responsiveness to methadone maintenance treatment (MMT) center in Israel. Int J Addict 25(11a):20Google Scholar
  33. 33.
    Havens J, Latkin C, Pu M, Cornelius L, Bishai D, Huettner S et al (2009) Predictors of opiate agonist treatment retention among injection drug users referred from a needle exchange program. J Subst Abuse Treat 36(3):6CrossRefGoogle Scholar
  34. 34.
    Gerra G, Di Petta G, D’Amore A, Iannotta P, Bardicchia F, Falorni F et al (2007) Combination of olanzapine with opioid-agonists in the treatment of heroin-addicted patients affected by comorbid schizophrenia spectrum disorders. Clin Neuropharmacol 30(3):8CrossRefGoogle Scholar
  35. 35.
    Feinberg D, Hartman N (1991) Methadone and schizophrenia. Am J Psychiatry 148(12):2Google Scholar
  36. 36.
    Fareed A, Vayalapalli S, Stout S, Casarella J, Drexler K, Bailey S (2011) Effect of methadone maintenance treatment on heroin craving, a literature review. J Addict Dis 30(1):11Google Scholar
  37. 37.
    Carcoba L, Contreras A, Cepeda-Benito A, Meagher M (2011) Negative affect heightens opiate withdrawal-induced hyperalgesia in heroin dependent individuals. J Addict Dis 30(3):2CrossRefGoogle Scholar
  38. 38.
    Grüsser S, Mörsen C, Wölfling K, Flor H (2007) The relationship of stress, coping, effect expectancies and craving. Eur Addict Res 13(1):7Google Scholar
  39. 39.
    Rang H, Dale M (2011) Rang and Dale’s pharmacology, 7th edn. Saunders Elsevier, St. LouisGoogle Scholar

Copyright information

© Royal Academy of Medicine in Ireland 2015

Authors and Affiliations

  • C. D. Darker
    • 1
    Email author
  • J. Ho
    • 1
  • G. Kelly
    • 1
  • L. Whiston
    • 1
  • J. Barry
    • 1
  1. 1.Department of Public Health and Primary Care, Trinity Centre for Health SciencesTrinity College Dublin, Tallaght HospitalDublin 24Ireland

Personalised recommendations